Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-04-01

FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Kesimpta (ofatumumab) by Novartis Pharmaceuticals Corporation. This approval indicates an updated label, potenti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Kesimpta (ofatumumab)

Snippet

SUPPL AP for KESIMPTA (OFATUMUMAB)